Clinical Trials on Red Blood Cell Survival in Denmark

Total 316 results

Blueprint Medicines Corporation

Active, not recruiting

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States, Canada, United Kingdom, France, Netherlands, Italy, Spain, Austria, Denmark, Germany, Norway, Poland
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab

Multiple Myeloma

Korea, Republic of, Russian Federation, Spain, Germany, Belgium, Denmark, Greece, France, United States, Ukraine, Poland
Charite University, Berlin, Germany
European Organisation for Research and Treatment of Cancer - EORTC; Centre... and other collaborators

Completed

International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010

Acute Lymphoblastic Leukemia (ALL)

United Kingdom, Norway, Germany, Italy, France, Belgium, Denmark, Australia, Austria, Czechia, Finland, Israel, Japan, Netherlands, Poland, Portugal, Switzerland
TeneoOne Inc.

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel, United States, Canada, Spain, France, Denmark, United Kingdom
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, China, Belgium, Germany, Spain, Israel, Turkey, Ukraine, Japan, Taiwan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, Brazil, Russian Federation, Argentina, Norway, Swed... and more
Hoffmann-La Roche

Recruiting

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Large B-Cell Lymphoma

Belgium, Korea, Republic of, China, Japan, Australia, United States, Italy, Spain, Taiwan, United Kingdom, Germany, France, Canada, Mexico, Poland, Turkey, Switzerland, Brazil, Argentina, Denmark
Celgene

Terminated

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)

Multiple Myeloma

United States, Canada, Spain, Italy, Denmark, United Kingdom, Belgium, Sweden, Germany
Hoffmann-La Roche
Fondazione Italiana Linfomi ONLUS

Terminated

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Diffuse Large B-Cell Lymphoma

Italy, China, Korea, Republic of, Canada, Australia, United States, Austria, Brazil, Denmark, Panama, Peru, Spain, Colombia, United Kingdom, Switzerland, Thailand, Mexico, Taiwan, Hong Kong, Russian Federation, Hungary, Japan, Germany, South Africa and more
Mats Heyman
Nordic Society for Pediatric Hematology and Oncology; NordForsk; The Swedish...

Recruiting

A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Leukemia, Acute Lymphoblastic

Estonia, Spain, Finland, Denmark, Iceland, Lithuania, Norway, Sweden
St. Anna Kinderkrebsforschung

Unknown

ALL-SCT BFM International- HSCT in Children and Adolescents With ALL (ALL-SCT-BFMi)

Lymphoblastic Leukemia, Acute, Childhood;

Israel, Austria, Czech Republic, Denmark, France, Italy, Netherlands, Poland, Slovakia, Sweden, Turkey
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor ((CITADEL-205))

Lymphoma

United States, Spain, France, United Kingdom, Czechia, Israel, Belgium, Italy, Germany, Poland, Denmark
Celgene

Completed

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (Sprint)

Lymphoma, Mantle-Cell | Mantle Cell Lymphoma

France, United Kingdom, Belgium, Spain, Denmark, Germany, Israel, Russian Federation, Italy, Poland, Netherlands, Sweden, Greece, Czechia
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
Hoffmann-La Roche

Recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Belgium, Australia, Denmark, Spain, Taiwan, France, Italy, United States, Canada, Czechia, New Zealand, Poland, Finland
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
Genmab
AbbVie

Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Diffuse Large B-Cell Lymphoma

Korea, Republic of, Spain, Japan, Israel, Australia, Poland, Netherlands, Sweden, Greece, Taiwan, Italy, Denmark, Switzerland, France, Bulgaria, Hungary, Austria, New Zealand, Czechia, Croatia, Belgium, Brazil, China, United States, Canada and more
Celgene

Active, not recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Multiple Myeloma

United States, Canada, Italy, Czechia, Denmark, France, Germany, Greece, Spain
Hoffmann-La Roche

Completed

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma

Hong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
AbbVie

Active, not recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Acute Myeloid Leukemia | Cancer | Multiple Myeloma | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States, Australia, Belgium, Canada, Denmark, France, Greece, Hong Kong, Ireland, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Portugal, Russian Federation, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Au...
Takeda

Active, not recruiting

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Multiple Myeloma | Autologous Stem Cell Transplant

United States, Spain, Australia, Czechia, Hungary, Taiwan, Italy, Denmark, Portugal, Singapore, Israel, Canada, France, Belgium, United Kingdom, Germany, Japan, Austria, Netherlands, Korea, Republic of, Poland, Greece, Colombia, Sweden, South Africa and more
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

B-cell Chronic Lymphocytic Leukemia

United States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
Celgene

Active, not recruiting

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

United States, Canada, Denmark, Australia, Belgium, Finland, Greece, Japan, Korea, Republic of, Spain, United Kingdom
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Lymphoma

Belgium, United States, France, Israel, Italy, United Kingdom, Germany, Spain, Poland, Australia, Argentina, Denmark
Hoffmann-La Roche

Completed

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Non-Small-Cell Lung Carcinoma

United States, Spain, France, Italy, Belgium, Korea, Republic of, Taiwan, United Kingdom, Luxembourg, Australia, Netherlands, Germany, Singapore, Denmark, Russian Federation, Sweden
Celgene

Recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

Korea, Republic of, Canada, United States, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Japan, Malaysia, Mexico, New Zealand, Norway, Polan... and more
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
Octapharma

Recruiting

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Chronic Lymphocytic Leukemia | Hypogammaglobulinemia

United States, Denmark, Germany, Hungary, Italy, Poland, Russian Federation, Spain, Czechia, Greece, Israel, Turkey
Celgene

Completed

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) (ORIGIN)

B-Cell Chronic Lymphocytic Leukemia

United States, Spain, Australia, Belgium, Italy, Serbia, Poland, Israel, New Zealand, Portugal, Brazil, France, Bulgaria, Croatia, Czechia, Hungary, Russian Federation, Netherlands, Romania, Denmark, United Kingdom, Austria, Canada, South... and more
Amgen

Active, not recruiting

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet (SELECT)

Relapsed or Refractory Multiple Myeloma

United States, Spain, Germany, France, Italy, Denmark, Greece, Estonia
AbbVie

Completed

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) (VENICE I)

Chronic Lymphocytic Leukemia

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Norway, Portugal, Puerto Rico, Spain, Sweden, Switzerland, Turkey, United Kingdom
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, Spain, Belgium, Canada, United Kingdom, Australia, Denmark, Poland, Ireland, France, Sweden
Sanofi

Active, not recruiting

A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

Plasma Cell Myeloma

Italy, Korea, Republic of, Norway, Canada, Spain, Germany, Greece, Lithuania, Sweden, Israel, Hungary, France, Japan, Australia, China, Denmark, Czechia, Turkey, United States, Brazil, Ireland, New Zealand, Poland, United Kingdom
Hoffmann-La Roche
Genentech, Inc.; Biogen

Completed

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Chronic Lymphocytic Leukemia

United States, Italy, Belgium, Canada, Spain, Australia, France, Russian Federation, Netherlands, New Zealand, Denmark, Romania, Poland, Hungary, United Kingdom, Sweden, Norway
AbbVie
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, Denmark, France, Germany, Japan
Celgene

Completed

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Multiple Myeloma

Canada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
Hoffmann-La Roche
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia (CLL-8)

Leukemia

France, Australia, Belgium, Italy, Germany, Israel, New Zealand, Czech Republic, Spain, Austria, Denmark
GlaxoSmithKline

Completed

Observational Study of Nelarabine in Children and Young Adults

Leukaemia, Lymphoblastic, Acute

Russian Federation, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)

Multiple Myeloma

United States, Netherlands, Belgium, Korea, Republic of, United Kingdom, Sweden, Denmark, Italy, Japan, Germany, France, Spain, Australia, Israel, Poland, Greece
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

Lymphoma, Mantle-Cell

United States, China, Spain, Belgium, Canada, Australia, Czechia, Italy, Taiwan, Germany, Japan, New Zealand, United Kingdom, Denmark, Brazil, Israel, France, Netherlands, Korea, Republic of, Poland, Hungary, Austria, Switzerland, Por... and more
Janssen Research & Development, LLC

Terminated

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Multiple Myeloma

Canada, United States, Belgium, Poland, Italy, France, Spain, Brazil, Russian Federation, Denmark, Greece, Germany, Netherlands
Celgene

Completed

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma (STRATUS)

Multiple Myeloma

Netherlands, Spain, Belgium, Austria, Switzerland, Italy, Germany, France, Ireland, United Kingdom, Denmark, Finland, Portugal, Turkey, Poland, Estonia, Greece, Norway, Slovakia, Sweden
Celgene

Completed

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (NIMBUS)

Multiple Myeloma

United States, Netherlands, Canada, Belgium, United Kingdom, Australia, Denmark, Germany, Spain, Switzerland, France, Italy, Greece, Russian Federation, Sweden, Czechia
Celgene

Active, not recruiting

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Multiple Myeloma

Netherlands, Belgium, Denmark, Germany, United Kingdom, France, Norway, Spain, Austria, Ireland, Italy, Sweden
Oncopeptides AB

Terminated

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN)

Multiple Myeloma

United States, Austria, Belgium, Czechia, Denmark, Estonia, France, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom
Novartis Pharmaceuticals
Children's Oncology Group

Recruiting

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)

B-Cell Acute Lymphoblastic Leukemia

United States, Netherlands, Italy, Germany, Belgium, Canada, France, Spain, United Kingdom, Finland, Denmark, Sweden, Norway
Celgene Corporation

Completed

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Newly Diagnosed Multiple Myeloma

Spain, Netherlands, Austria, Australia, Italy, Russian Federation, United Kingdom, Israel, Belgium, Greece, Germany, Poland, Turkey, France, Denmark, Czech Republic, Belarus, Georgia, Ireland, Sweden, Switzerland, Ukraine
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Non-Hodgkins Lymphoma | Hematologic Malignancies | Chronic Lymphocytic Leukaemia | Waldenstroms Macroglobulinaemia

Poland, United States, Argentina, Australia, Brazil, Canada, France, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom, Korea, Republic of, Germany, Denmark, China, Romania, Czechia, Hungary, Ireland, Ukraine
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

Leukemia, Lymphocytic, Chronic, B-Cell

Canada, Belgium, Netherlands, Spain, Israel, United States, Czechia, Denmark, United Kingdom, France, Russian Federation, Turkey, Poland, Sweden
Janssen Research & Development, LLC

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Multiple Myeloma

United States, Korea, Republic of, Denmark, Czechia, Israel, Switzerland, Belgium, United Kingdom, Japan, Argentina, Sweden, Canada, Spain, Germany, Netherlands, France, Brazil, Greece, Poland, Ireland, Hungary, Portugal, Australia, F... and more

Clinical Trials on Red Blood Cell Survival in Denmark

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations